Base de dados : MEDLINE
Pesquisa : C15.378.553.475.604 [Categoria DeCS]
Referências encontradas : 2448 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 245 ir para página                         

  1 / 2448 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28846923
[Au] Autor:Kuchler L; Sha LK; Giegerich AK; Knape T; Angioni C; Ferreirós N; Schmidt MV; Weigert A; Brüne B; von Knethen A
[Ad] Endereço:Institute of Biochemistry I - Pathobiochemistry, Faculty of Medicine, Goethe-University Frankfurt, 60590 Frankfurt, Germany.
[Ti] Título:Elevated intrathymic sphingosine-1-phosphate promotes thymus involution during sepsis.
[So] Source:Mol Immunol;90:255-263, 2017 Oct.
[Is] ISSN:1872-9142
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Sepsis mouse models revealed thymus atrophy, characterised by decreased thymus weight and loss of thymocytes due to apoptosis. Mice suffered from lymphopenia, a lack of T cells in the periphery, which attenuates their ability to fight against recurring and secondary infections during sepsis progression. Key players in thymus atrophy are IL-6, which is directly involved in thymus involution, and the sphingosine-1-phosphate - sphingosine-1-phosphate receptor 1 signaling, influencing thymocytes emigration. In healthy individuals a sphingosine-1-phosphate (S1P) gradient from lymphoid organs to the circulatory system serves as signal for mature T cell egress. In the present study we investigated, whether inhibition of S1P generation improves thymus involution. In sepsis, induced by cecal ligation and puncture (CLP), S1P in the thymus increased, while it decreased in serum, thus disrupting the naturally occurring S1P gradient. As a potential source of S1P we identified increased numbers of apoptotic cells in the thymic cortex of septic mice. Pharmacological inhibition of the S1P generating sphingosine kinases, by 4- [[4-(4-Chlorophenyl)-2-thiazolyl]amino]phenol (SK I-II), administered directly following CLP, prevented thymus atrophy. This was reflected by lymphocytosis, diminished apoptosis, decreased IL-6 expression, and an unaltered thymus weight. In addition SK I-II-treatment preserved the S1P balance and prevented S1P-dependent internalization of the sphingosine-1-phosphate receptor 1. Our data suggest that inhibition of sphingosine kinase and thus, S1P generation during sepsis restores thymic T cell egress, which might improve septic outcome.
[Mh] Termos MeSH primário: Apoptose/efeitos dos fármacos
Apoptose/fisiologia
Lisofosfolipídeos/sangue
Lisofosfolipídeos/metabolismo
Fosfotransferases (Aceptor do Grupo Álcool)/antagonistas & inibidores
Sepse/patologia
Esfingosina/análogos & derivados
Timócitos/metabolismo
Timo/patologia
[Mh] Termos MeSH secundário: Aminofenóis/farmacologia
Animais
Atrofia/patologia
Atrofia/prevenção & controle
Ceco/cirurgia
Modelos Animais de Doenças
Interleucina-6/biossíntese
Interleucina-6/imunologia
Linfocitose
Linfopenia
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Receptores de Lisoesfingolipídeo/metabolismo
Esfingosina/sangue
Esfingosina/metabolismo
Tiazóis/farmacologia
Timócitos/citologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (4-((4-(4-chlorophenyl)-2-thiazolyl)amino)phenol); 0 (Aminophenols); 0 (Interleukin-6); 0 (Lysophospholipids); 0 (Receptors, Lysosphingolipid); 0 (Thiazoles); 0 (interleukin-6, mouse); 26993-30-6 (sphingosine 1-phosphate); EC 2.7.1.- (Phosphotransferases (Alcohol Group Acceptor)); EC 2.7.1.- (sphingosine kinase); NGZ37HRE42 (Sphingosine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170829
[St] Status:MEDLINE


  2 / 2448 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28787254
[Au] Autor:Hopf F; Thomas P; Sesselmann S; Thomsen MN; Hopf M; Hopf J; Krukemeyer MG; Resch H; Krenn V
[Ad] Endereço:a Center for Histopathology and Molecular Pathology , Trier , Germany.
[Ti] Título:CD3+ lymphocytosis in the peri-implant membrane of 222 loosened joint endoprostheses depends on the tribological pairing.
[So] Source:Acta Orthop;88(6):642-648, 2017 Dec.
[Is] ISSN:1745-3682
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background and purpose - The most frequent cause of arthroplasty failure is aseptic loosening-often induced by particles. Abrasion material triggers inflammatory reactions with lymphocytic infiltration and the formation of synovial-like interface membranes (SLIM) in the bone-implant interface. We analyzed CD3 quantities in SLIM depending on articulating materials and possible influences of proven material allergies on CD3 quantities. Patients and methods - 222 SLIM probes were obtained from revision surgeries of loosened hip and knee arthroplasties. SLIM cases were categorized according to the SLIM-consensus classification and to the particle algorithm. The CD3 quantities were analyzed immunohistochemically, quantified, and correlated to the particle types. Results - Metal-metal pairings showed the highest CD3 quantities (mean 1,367 counted cells). CD3 quantities of metal-polyethylene (mean 243), ceramic-polyethylene (mean 182), and ceramic-ceramic pairings (mean 124) were significantly smaller. Patients with contact allergy to implant materials had high but not statistically significantly higher CD3 quantities than patients without allergies. For objective assessment of the CD3 response as result of a pronounced inflammatory reaction with high lymphocytosis (adverse reaction), a defined CD3 quantity per high power field was established, the "CD3 focus score" (447 cells/0.3 mm , sensitivity 0.92; specificity 0.90; positive predictive value 0.71; negative predictive value 0.98). Interpretation - The high CD3 quantities for metal-metal pairings may be interpreted as substrate for previously described adverse reactions that cause severe peri-implant tissue destruction and SLIM formation. It remains unclear whether the low CD3 quantities with only slight differences in the various non-metal-metal pairings and documented contact allergies to implant materials have a direct pathogenetic relevance.
[Mh] Termos MeSH primário: Artroplastia de Quadril/efeitos adversos
Artroplastia do Joelho/efeitos adversos
Complexo CD3/imunologia
Linfocitose/imunologia
Membrana Sinovial/imunologia
Linfócitos T/imunologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Prótese de Quadril/efeitos adversos
Seres Humanos
Imuno-Histoquímica
Contagem de Linfócitos
Linfocitose/diagnóstico
Linfocitose/etiologia
Masculino
Meia-Idade
Falha de Prótese
Membrana Sinovial/patologia
Linfócitos T/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CD3 Complex)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170809
[St] Status:MEDLINE
[do] DOI:10.1080/17453674.2017.1362774


  3 / 2448 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28731904
[Au] Autor:Alfano G; Fontana F; Colaci E; Messerotti A; Bettelli F; Potenza L; Luppi M; Cappelli G
[Ad] Endereço:1 Nephrology Dialysis and Transplant Unit, University Hospital of Modena, Modena, Italy. 2 Surgical, Medical and Dental Department of Morphological Sciences, Section of Nephrology, University of Modena and Reggio Emilia, Modena, Italy. 3 Surgical, Medical and Dental Department of Morphological Sciences, Section of Hematology, University Hospital of Modena and Reggio Emilia, Modena, Italy.
[Ti] Título:Monoclonal Gammopathy of Undetermined Significance After Kidney Transplantation: Single-Center Experience.
[So] Source:Transplantation;101(11):e337-e342, 2017 Nov.
[Is] ISSN:1534-6080
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant plasma cell disorder. Prevalence and clinical outcomes of MGUS in kidney transplant (KT) recipients have been previously reported in few studies with conflicting results. METHODS: We conducted a retrospective study in a population of 548 KT recipients transplanted between 1998 and 2015. RESULTS: Thirty-nine (8.1%) subjects developed MGUS after KT. At diagnosis of MGUS, the average age was 52 ± 9.2 years, and 23% of the patients were younger than 50 years. Occurrence of MGUS was not influenced by age and sex. After a mean follow-up of 7.8 years, only 1 (2.5%) patient progressed to multiple myeloma. We found no differences in the incidence of solid and hematological malignancies, serious infections, graft failure, and mortality between KT patients with MGUS and a matched cohort of KT recipients without MGUS. The MGUS group had a significantly higher prevalence of monoclonal B cell lymphocytosis, premalignant condition poorly described in KT recipients. Prior history of glomerulonephritis or interstitial nephritis, as cause of renal failure, represented the only predictive factor for MGUS development. CONCLUSIONS: MGUS is a premalignant disorder frequently encountered in KT recipients. We found no differences in clinical outcomes between MGUS patients and KT controls.
[Mh] Termos MeSH primário: Transplante de Rim/efeitos adversos
Gamopatia Monoclonal de Significância Indeterminada/epidemiologia
Lesões Pré-Cancerosas/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Progressão da Doença
Feminino
Sobrevivência de Enxerto
Seres Humanos
Itália/epidemiologia
Estimativa de Kaplan-Meier
Transplante de Rim/mortalidade
Linfocitose/epidemiologia
Linfocitose/imunologia
Masculino
Meia-Idade
Gamopatia Monoclonal de Significância Indeterminada/diagnóstico
Gamopatia Monoclonal de Significância Indeterminada/imunologia
Gamopatia Monoclonal de Significância Indeterminada/mortalidade
Mieloma Múltiplo/epidemiologia
Mieloma Múltiplo/imunologia
Lesões Pré-Cancerosas/diagnóstico
Lesões Pré-Cancerosas/imunologia
Lesões Pré-Cancerosas/mortalidade
Prevalência
Prognóstico
Estudos Retrospectivos
Fatores de Risco
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170722
[St] Status:MEDLINE
[do] DOI:10.1097/TP.0000000000001884


  4 / 2448 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28423121
[Au] Autor:Furtado FM; Scheucher PS; Santana BA; Scatena NF; Calado RT; Rego EM; Matos DM; Falcão RP
[Ad] Endereço:Divisão de Hematologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.
[Ti] Título:Telomere length analysis in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Binet A.
[So] Source:Braz J Med Biol Res;50(5):e6019, 2017 Apr 13.
[Is] ISSN:1414-431X
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Monoclonal B-cell lymphocytosis (MBL) is an asymptomatic clinical entity characterized by the proliferation of monoclonal B cells not meeting the diagnosis criteria for chronic lymphocytic leukemia (CLL). MBL may precede the development of CLL, but the molecular mechanisms responsible for disease progression and evolution are not completely known. Telomeres are usually short in CLL and their attrition may contribute to disease evolution. Here, we determined the telomere lengths of CD5+CD19+ cells in MBL, CLL, and healthy volunteers. Twenty-one CLL patients, 11 subjects with high-count MBL, and 6 with low-count MBL were enrolled. Two hundred and sixty-one healthy volunteers aged 0 to 88 years were studied as controls. After diagnosis confirmation, a flow cytometry CD19+CD5+-based cell sorting was performed for the study groups. Telomere length was determined by qPCR. Telomere length was similar in the 3 study groups but shorter in these groups compared to normal age-matched subjects that had been enrolled in a previous study from our group. These findings suggest that telomere shortening is an early event in CLL leukemogenesis.
[Mh] Termos MeSH primário: Linfócitos B/patologia
Leucemia Linfocítica Crônica de Células B/genética
Leucemia Linfocítica Crônica de Células B/patologia
Linfocitose/genética
Linfocitose/patologia
Encurtamento do Telômero/genética
[Mh] Termos MeSH secundário: Fatores Etários
Idoso
Idoso de 80 Anos ou mais
Estudos de Casos e Controles
Progressão da Doença
Feminino
Citometria de Fluxo
Marcadores Genéticos
Seres Humanos
Contagem de Linfócitos
Masculino
Meia-Idade
Padrões de Referência
Estatísticas não Paramétricas
Telômero/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Genetic Markers)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170831
[Lr] Data última revisão:
170831
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170420
[St] Status:MEDLINE


  5 / 2448 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28319486
[Au] Autor:Bozzalla Cassione E; Stone JH
[Ad] Endereço:Rheumatology Clinic/Yawkey 2, Massachusetts General Hospital, Boston, Massachusetts, USA.
[Ti] Título:IgG4-related disease.
[So] Source:Curr Opin Rheumatol;29(3):223-227, 2017 May.
[Is] ISSN:1531-6963
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE OF REVIEW: Remarkable insights have been gleaned recently with regard to the pathophysiology of IgG4-related disease (IgG4-RD). These findings have direct implications for the development of targeted strategies for the treatment of this condition. RECENT FINDINGS: Oligoclonal expansions of cells of both the B and T lymphocyte lineages are present in the blood of patients with IgG4-RD. Oligoclonal expansions of plasmablasts are a good biomarker for disease activity. An oligoclonally expanded population of CD4+ cytotoxic T lymphocytes is found not only in the peripheral blood but also at tissue sites of active disease. This cell elaborates cytokines that may drive the fibrosis characteristic of IgG4-RD. T follicular helper cells (Tfhc), particularly the Tfhc2 subset, appear to play a major role in driving the class switch to IgG4 that typifies this disease. The relationship between malignancy and IgG4-RD remains an area of interest. SUMMARY: Advances in understanding the pathophysiology of IgG4-RD have proceeded swiftly, leading to the identification of a number of potential targeted treatment strategies. The completion of classification criteria for IgG4-RD, an effort supported jointly by the American College of Rheumatology and the European League Against Rheumatism, will further facilitate studies on this disease.
[Mh] Termos MeSH primário: Linfócitos T CD4-Positivos/imunologia
Imunoglobulina G/sangue
Linfocitose/imunologia
Plasmócitos/imunologia
[Mh] Termos MeSH secundário: Citocinas/metabolismo
Seres Humanos
Linfocitose/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cytokines); 0 (Immunoglobulin G)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170705
[Lr] Data última revisão:
170705
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170321
[St] Status:MEDLINE
[do] DOI:10.1097/BOR.0000000000000383


  6 / 2448 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28288720
[Au] Autor:Xochelli A; Oscier D; Stamatopoulos K
[Ad] Endereço:Institute of Applied Biosciences, CERTH, Thessaloniki, Greece; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
[Ti] Título:Clonal B-cell lymphocytosis of marginal zone origin.
[So] Source:Best Pract Res Clin Haematol;30(1-2):77-83, 2017 Mar - Jun.
[Is] ISSN:1532-1924
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Monoclonal B cell Lymphocytosis (MBL) is the term used to characterize individuals presenting with lymphocytosis in the absence of lymphadenopathy, organomegaly or any other features suggestive of an active disease. Based on the immunophenotypic findings, MBL cases are sub-categorized into chronic lymphocytic leukemia (CLL)-like, atypical CLL and non-CLL MBL. The latter corresponds to cases with immunophenotypic features suggestive of post germinal center derivation and still represents a diagnostic conundrum. Recent studies are starting to shed light on the true biological nature and clinical significance of this entity and have led to the introduction of the novel term clonal B lymphocytosis of marginal-zone origin (CBL-MZ); as well as the acknowledgement of CBL-MZ in the latest (2016) update of the WHO classification for lymphoid malignancies. Here we provide an overview of relevant research concerning non-CLL MBL and discuss clinico-biological implications and considerations.
[Mh] Termos MeSH primário: Linfócitos B/imunologia
Linfocitose
[Mh] Termos MeSH secundário: Seres Humanos
Leucemia Linfocítica Crônica de Células B/classificação
Leucemia Linfocítica Crônica de Células B/diagnóstico
Leucemia Linfocítica Crônica de Células B/imunologia
Linfocitose/classificação
Linfocitose/diagnóstico
Linfocitose/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171009
[Lr] Data última revisão:
171009
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170315
[St] Status:MEDLINE


  7 / 2448 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28274529
[Au] Autor:Enomoto Y; Nakamura Y; Enomoto N; Fujisawa T; Inui N; Suda T
[Ad] Endereço:Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Japan.
[Ti] Título:Japanese herbal medicine-induced pneumonitis: A review of 73 patients.
[So] Source:Respir Investig;55(2):138-144, 2017 03.
[Is] ISSN:2212-5353
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The number of reports concerning Japanese herbal medicine (JHM)-induced pneumonitis has increased. However, comprehensive data are lacking in this regard, and the clinical characteristics of the disease remain unclear. METHODS: A literature review was performed using PubMed and Ichushi-Web-the database of the Japan Medical Abstracts Society-to identify articles published between 1996 and 2015 describing patients with JHM-induced pneumonitis. The final cohort included 73 patients in 59 articles (7 in English; 52 in Japanese). RESULTS: Among the various JHMs reported, sho-saiko-to was the most frequently used drug (26%), followed by sairei-to (16%), seishin-renshi-in (8%), and bofu-tsusyo-san (8%). These drugs commonly contain ougon (skullcap) and kanzo (liquorice). The mean age at pneumonitis diagnosis was 63.2 ± 15.5 years (range: 7-89 years). The male/female ratio was 44/29. Sixty-five patients (89%) developed pneumonitis within 3 months of beginning JHM treatment. Bilateral ground-glass attenuations on chest computed tomography, as well as lymphocytosis with a low CD4/CD8 T-cell ratio in bronchoalveolar lavage fluid, were common findings. Twenty-six patients (36%) recovered from the pneumonitis after simply discontinuing the causative JHM. However, the remainder required immunosuppressive therapy, and 13 patients (18%) received mechanical ventilation. Importantly, three patients (4%) did not survive, with two showing pathological diffuse alveolar damage upon autopsy. CONCLUSIONS: Clinicians should be cautious regarding JHM-induced pneumonitis, particularly when using drugs/ingredients known to cause this complication, and during the early treatment period. Although most events are non-severe, critical cases should be recognized.
[Mh] Termos MeSH primário: Medicamentos de Ervas Chinesas/efeitos adversos
Pneumonia/induzido quimicamente
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Relação CD4-CD8
Criança
Medicamentos de Ervas Chinesas/química
Feminino
Seres Humanos
Linfocitose
Masculino
Meia-Idade
Pneumonia/diagnóstico
Pneumonia/epidemiologia
Radiografia Torácica
Tomografia Computadorizada por Raios X
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Drugs, Chinese Herbal); 0 (bofu-tsusho-san); 0 (sairei-to); 0 (shosaiko-to)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170310
[St] Status:MEDLINE


  8 / 2448 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28249016
[Au] Autor:García-Álvarez M; Alcoceba M; López-Parra M; Puig N; Antón A; Balanzategui A; Prieto-Conde I; Jiménez C; Sarasquete ME; Chillón MC; Gutiérrez ML; Corral R; Alonso JM; Queizán JA; Vidán J; Pardal E; Peñarrubia MJ; Bastida JM; García-Sanz R; Marín L; González M
[Ad] Endereço:Department of Hematology, University Hospital of Salamanca (HUS-IBSAL), Salamanca, Spain.
[Ti] Título:HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis.
[So] Source:PLoS One;12(3):e0172978, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Molecular alterations leading progression of asymptomatic CLL-like high-count monoclonal B lymphocytosis (hiMBL) to chronic lymphocytic leukemia (CLL) remain poorly understood. Recently, genome-wide association studies have found 6p21.3, where the human leukocyte antigen (HLA) system is coded, to be a susceptibility risk region for CLL. Previous studies have produced discrepant results regarding the association between HLA and CLL development and outcome, but no studies have been performed on hiMBL. AIMS: We evaluated the role of HLA class I (-A, -B and -C) and class II (-DRB1 and -DQB1) in hiMBL/CLL susceptibility, hiMBL progression to CLL, and treatment requirement in a large series of 263 patients diagnosed in our center with hiMBL (n = 156) or Binet A CLL (n = 107). RESULTS: No consistent association between HLA specificities and hiMBL or CLL susceptibility was found. With a median follow-up of 7.7 years, 48/156 hiMBLs (33%) evolved to asymptomatic CLLs, while 16 hiMBLs (10%) and 44 CLLs (41%) required treatment. No HLA specificities were found to be significantly associated with hiMBL progression or treatment in the whole cohort. However, within antigen-experienced immunoglobulin heavy-chain (IGHV)-mutated hiMBLs, which represents the highest proportion of hiMBL cases (81%), the presence of HLA-DQB1*03 showed a trend to a higher risk of progression to CLL (60% vs. 26%, P = 0.062). Moreover, HLA-DQB1*02 specificity was associated with a lesser requirement for 15-year treatment (10% vs. 36%, P = 0.012). CONCLUSION: In conclusion, our results suggest a role for HLA in IGHV-mutated hiMBL prognosis, and are consistent with the growing evidence of the influence of 6p21 on predisposition to CLL. Larger non-biased series are required to enable definitive conclusions to be drawn.
[Mh] Termos MeSH primário: Genes de Cadeia Pesada de Imunoglobulina
Antígenos de Histocompatibilidade Classe I/genética
Linfocitose/genética
Mutação
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Linfócitos B/patologia
Cromossomos Humanos Par 6/genética
Feminino
Seres Humanos
Contagem de Linfócitos
Linfocitose/sangue
Masculino
Meia-Idade
Prognóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Histocompatibility Antigens Class I)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170302
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0172978


  9 / 2448 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28246468
[Au] Autor:Rouphael C; Gordon IO; Thota PN
[Ad] Endereço:Carol Rouphael, Department of General Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, United States.
[Ti] Título:Lymphocytic esophagitis: Still an enigma a decade later.
[So] Source:World J Gastroenterol;23(6):949-956, 2017 Feb 14.
[Is] ISSN:2219-2840
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Lymphocytic esophagitis (LE) is a clinicopathologic entity first described by Rubio et al in 2006. It is defined as peripapillary intraepithelial lymphocytosis with spongiosis and few or no granulocytes on esophageal biopsy. This definition is not widely accepted and the number of lymphocytes needed to make the diagnosis varied in different studies. Multiple studies have described potential clinical associations and risk factors for LE, such as old age, female gender and smoking history. This entity was reported in inflammatory bowel disease in the pediatric population but not in adults. Other associations include gastroesophageal reflux disease and primary esophageal motility disorders. The most common symptom is dysphagia, with a normal appearing esophagus on endoscopy, though esophageal rings, webs, nodularities, furrows and strictures have been described. Multiple treatment modalities have been used such as proton pump inhibitors and topical steroids. Esophageal dilation seems to be therapeutic when dysphagia is present along with esophageal narrowing secondary to webs, rings or strictures. The natural history of the disease remains unclear and needs to be better delineated. Overall, lymphocytic esophagitis seems to have a chronic and benign course, except for two cases of esophageal perforation in the literature, thought to be secondary to this entity.
[Mh] Termos MeSH primário: Transtornos da Motilidade Esofágica/complicações
Esofagite/etiologia
Refluxo Gastroesofágico/complicações
Linfocitose/etiologia
[Mh] Termos MeSH secundário: Biópsia
Toxinas Botulínicas Tipo A/uso terapêutico
Endoscopia
Esofagite/diagnóstico
Esofagite/tratamento farmacológico
Esofagite/patologia
Glucocorticoides/uso terapêutico
Seres Humanos
Linfocitose/diagnóstico
Linfocitose/tratamento farmacológico
Linfocitose/patologia
Inibidores da Bomba de Prótons/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Glucocorticoids); 0 (Proton Pump Inhibitors); E211KPY694 (onabotulinumtoxinA); EC 3.4.24.69 (Botulinum Toxins, Type A)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170302
[St] Status:MEDLINE
[do] DOI:10.3748/wjg.v23.i6.949


  10 / 2448 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28240053
[Au] Autor:Gusella M; Bolzonella C; Paolini R; Rodella E; Bertolaso L; Scipioni C; Bellini S; Cuneo A; Pasini F; Ramazzina E
[Ad] Endereço:1 Department of Oncology, Azienda ULSS 18 Rovigo, Rovigo, Italy.
[Ti] Título:Plasma matrix metalloprotease 9 correlates with blood lymphocytosis, leukemic cell invasiveness, and prognosis in B-cell chronic lymphocytic leukemia.
[So] Source:Tumour Biol;39(2):1010428317694325, 2017 Feb.
[Is] ISSN:1423-0380
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The complex biology underlying chronic lymphocytic leukemia cell migration and tissue invasiveness is not yet completely understood and might provide novel predictive markers and therapeutic targets. A total of 36 patients out of treatment from at least 3 months were enrolled and followed up for a median period of 44.2 months (range: 4.4-99.2). Matrix metalloprotease 9 and tissue inhibitor of metalloproteases 1 plasma levels and production/release from lymphoid cells were measured by zymography and enzyme-linked immunosorbent assay (ELISA) analysis. Malignant and normal lymphocyte mobility and matrix-degradation capability were studied using a Boyden chamber system, with and without autologous plasma. Free matrix metalloprotease 9 plasma levels were related with blood lymphocytosis, especially in more advanced stages (p = 0.003), and higher concentrations were associated with an increased disease progression risk (hazard ratio = 9.0, 95% confidence interval = 1.5-13.8). Leukemic cells expressed and secreted very little matrix metalloprotease 9. On the contrary, normal lymphocytes derived from the same leukemic patients showed matrix metalloprotease 9 intracellular levels that were lower in subjects with higher blood lymphocytosis (p = 0.024) and more advanced stages (p = 0.03); the released quantities were inversely associated with matrix metalloprotease 9 plasma concentrations (p = 0.035). Leukemic cells had a reduced spontaneous mobility and matrix-degradation capability that were stimulated by autologous plasma (p = 0.001) and normal lymphocytes (p = 0.005), respectively. Matrix metalloprotease 9 affected cell invasiveness depending on concentration and disease stage. In conclusion, chronic lymphocytic leukemia cells have a reduced mobility, matrix-degradation capability, and matrix metalloprotease 9 production compared to their own autologous normal lymphocytes. They are exposed to matrix metalloprotease 9 of prevalently systemic origin whose higher levels are associated with both leukemic and normal lymphocyte accumulation in the peripheral blood and have a negative prognostic value.
[Mh] Termos MeSH primário: Leucemia Linfocítica Crônica de Células B/enzimologia
Linfocitose/enzimologia
Metaloproteinase 9 da Matriz/sangue
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Movimento Celular/fisiologia
Feminino
Seres Humanos
Leucemia Linfocítica Crônica de Células B/sangue
Leucemia Linfocítica Crônica de Células B/patologia
Linfocitose/sangue
Linfocitose/patologia
Masculino
Meia-Idade
Invasividade Neoplásica
Prognóstico
Inibidor Tecidual de Metaloproteinase-1/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (TIMP1 protein, human); 0 (Tissue Inhibitor of Metalloproteinase-1); EC 3.4.24.35 (MMP9 protein, human); EC 3.4.24.35 (Matrix Metalloproteinase 9)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170308
[Lr] Data última revisão:
170308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170228
[St] Status:MEDLINE
[do] DOI:10.1177/1010428317694325



página 1 de 245 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde